» Articles » PMID: 34359861

Cyclic AMP Signaling in Biliary Proliferation: A Possible Target for Cholangiocarcinoma Treatment?

Overview
Journal Cells
Publisher MDPI
Date 2021 Aug 7
PMID 34359861
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Cholangiocarcinoma is a lethal disease with scarce response to current systemic therapy. The rare occurrence and large heterogeneity of this cancer, together with poor knowledge of its molecular mechanisms, are elements contributing to the difficulties in finding an appropriate cure. Cholangiocytes (and their cellular precursors) are considered the liver component giving rise to cholangiocarcinoma. These cells respond to several hormones, neuropeptides and molecular stimuli employing the cAMP/PKA system for the translation of messages in the intracellular space. For instance, in physiological conditions, stimulation of the secretin receptor determines an increase of intracellular levels of cAMP, thus activating a series of molecular events, finally determining in bicarbonate-enriched choleresis. However, activation of the same receptor during cholangiocytes' injury promotes cellular growth again, using cAMP as the second messenger. Since several scientific pieces of evidence link cAMP signaling system to cholangiocytes' proliferation, the possible changes of this pathway during cancer growth also seem relevant. In this review, we summarize the current findings regarding the cAMP pathway and its role in biliary normal and neoplastic cell proliferation. Perspectives for targeting the cAMP machinery in cholangiocarcinoma therapy are also discussed.

Citing Articles

cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment.

Zhang H, Liu Y, Liu J, Chen J, Wang J, Hua H J Hematol Oncol. 2024; 17(1):5.

PMID: 38233872 PMC: 10792844. DOI: 10.1186/s13045-024-01524-x.


Sequence of events leading to primary biliary cholangitis.

Lenci I, Carni P, Milana M, Bicaj A, Signorello A, Baiocchi L World J Gastroenterol. 2023; 29(37):5305-5312.

PMID: 37899786 PMC: 10600805. DOI: 10.3748/wjg.v29.i37.5305.


Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss.

Ruland L, Andreatta F, Massalini S, Chuva de Sousa Lopes S, Clevers H, Hendriks D Nat Commun. 2023; 14(1):2377.

PMID: 37137901 PMC: 10156813. DOI: 10.1038/s41467-023-37951-6.


Biliary Epithelial Senescence in Liver Disease: There Will Be SASP.

Meadows V, Baiocchi L, Kundu D, Sato K, Fuentes Y, Wu C Front Mol Biosci. 2022; 8:803098.

PMID: 34993234 PMC: 8724525. DOI: 10.3389/fmolb.2021.803098.


Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling.

Gruttadauria S, Barbera F, Pagano D, Liotta R, Miraglia R, Barbara M Cancers (Basel). 2021; 13(23).

PMID: 34885159 PMC: 8657183. DOI: 10.3390/cancers13236049.

References
1.
Merkle D, Hoffmann R . Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor. Cell Signal. 2010; 23(3):507-15. DOI: 10.1016/j.cellsig.2010.08.017. View

2.
Deutschmann K, Reich M, Klindt C, Droge C, Spomer L, Haussinger D . Bile acid receptors in the biliary tree: TGR5 in physiology and disease. Biochim Biophys Acta Mol Basis Dis. 2017; 1864(4 Pt B):1319-1325. DOI: 10.1016/j.bbadis.2017.08.021. View

3.
Lenzen R, Alpini G, Tavoloni N . Secretin stimulates bile ductular secretory activity through the cAMP system. Am J Physiol. 1992; 263(4 Pt 1):G527-32. DOI: 10.1152/ajpgi.1992.263.4.G527. View

4.
Cohen J, Resnick D, Niewiadomski P, Dong H, Liau L, Waschek J . Pituitary adenylyl cyclase activating polypeptide inhibits gli1 gene expression and proliferation in primary medulloblastoma derived tumorsphere cultures. BMC Cancer. 2010; 10:676. PMC: 3016295. DOI: 10.1186/1471-2407-10-676. View

5.
Ding X, Saxena N, Lin S, Gupta N, Gupta N, Anania F . Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology. 2005; 43(1):173-81. PMC: 2925424. DOI: 10.1002/hep.21006. View